30 Years of Research and Clinical Trials
Geneaire ReBuilder™ is a new category of supplement to stabilize the longevity of neural/brain cells and resist degradation caused by aging and its related diseases. Its patented formulation of 13 natural interacting compounds has been created to stimulate specific human genomic sites identified as critical to the continued healthy function of brain cells as we grow older.
The discovery of approximately 500 genomic sites and the formulation that positively stimulates them is the result of over 30 years of scientific research and clinical trials conducted at University of California, Irvine, Genescient, Inc. and Hoag Hospital, CA. This research is summarized below and is also described in more detail in the downloadable White Paper: Geneaire ReBuilder™ White Paper - Oct 2018.
Stage 1: The “Methuselah Flies”
The common fruit fly (Drosophila Melanogaster) has been used for genetics research since the early 20th century.
By selectively breeding only longer-lived flies over 500 generations, researchers have extended the flies’ lifespans to three times that of normal flies.
Stage 2: Genome Analysis
Advanced Genome Analysis identifies several thousand sequence variations between “normal” and “Methuselah” fruit flies.
Use of the latest AI Machine Learning and Analytics techniques has enabled this list to be reduced to around 500 significant genomic sites.
Stage 3: Identifying Substance Candidates
Machine Learning was also used to identify potential substance candidates and predict the most effective formulations.
A patented formulation was identified of 13 interacting natural compounds from the FDA's GRAS List (Generally Regarded As Safe).
Ref: Multipath nutritional supplement for memory, cognition, and coordination - US patent 9,744,204. 2017.
Stage 4: Compound Testing
Fruit fly testing continues with the development of strains with specific age-related diseases such as Alzheimer’s, Dementia, and Parkinson’s. Flies are selectively bred with modified genomes and then used as test subjects for likely compound candidates.
Stage 5: Clinical Study
A 15-month clinical study was finalized by Hoag Hospital in 2015 to test the effect of this formula on a population of mild and moderate Alzheimer's patients.
The results were published in 2018 in the Journal of Clinical Medicine and Therapeutics.
Adding the formulation“stabilized cognitive decline in patients with mild AD and slowed cognitive decline in patients with moderate AD.”
The result of this research, Geneaire ReBuilder™ , is a complex supplement made from a patented formulation of 13 interacting compounds selected from the FDA’s GRAS List. It is therefore suitable for long term daily use with a focus on mitigating the neurological effects of aging rather than being a cure for any specific disease.
The study is referenced here, not to make any claims about Geneaire ReBuilder™ as a treatment for Alzheimer's or any other disease, but to demonstrate the depth of science-based research studying the formula's impact on longevity and later life brain function.